Parkinson’s Disease Therapeutics Market - 2024-2031

Parkinson’s Disease Therapeutics Market - 2024-2031

Global Parkinson’s disease therapeutics market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.

Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Studies have shown that symptoms of Parkinson's develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra.

The majority of Parkinson's patients are treated with medications to relieve the symptoms of the disease. These medications work by stimulating the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or by inhibiting some of the acetylcholine that is produced (anticholinergic medications), therefore restoring the balance between the chemicals in the brain. It is very important to work closely with the doctor to devise an individualized treatment plan.

Market Dynamics: Drivers

Introduction of novel therapeutics

The introduction of novel therapeutics is expected to drive the market over the forecast period. Novel therapeutics often target specific mechanisms underlying Parkinson's disease pathology, addressing unmet medical needs that existing treatments may not adequately fulfill. This can include targeting moror fluctuations, addressing symptoms or providing disease-modifying effects.

For instance, on January 9, 2024, AbbVie launched PRODUODOPA (foslevodopa/foscarbidopa) in the European Union for the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement), and when available combinations of Parkinson's medicinal products have not given satisfactory results. PRODUODOPA is the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations in people living with advanced Parkinson's disease whose symptoms are inadequately controlled by other therapies. The continuous delivery of PRODUODOPA provides levodopa 24 hours a day which may help patients by extending the period when symptoms are well-controlled, often referred to as ""On"" time.

Novel therapeutics may offer improved efficacy and safety profiles compared to existing treatments. This could involve targeting specific molecular pathways more precisely, reducing side effects, or providing sustained symptom relief with fewer adverse effects. For instance, on August 08, 2023, Aspen Neuroscience released that the United States Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for a new Parkinson’s Disease gene therapy. With this clearance secured, the company has the green light to begin clinical trials.

Many existing treatments for Parkinson's disease primarily focus on symptomatic relief. Novel therapeutics aim to go beyond symptom management by targeting disease-modifying mechanisms. This could potentially slow or halt disease progression, offering substantial benefits to patients and healthcare systems.

For instance, on July 2, 2024, UCB received an Import Drug License (IDL) from the China Food and Drug Administration (CFDA), creating a pathway to make the company’s 24-hour continuous delivery transdermal rotigotine patch NEUPRO available to patients in China. NEUPRO is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson’s Disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur. NEUPRO is designed to support and improve individual patient treatment experiences for people living with Parkinson’s Disease.

Further, the increasing prevalence of Parkinson’s disease, rising FDA approvals for novel therapies, increasing clinical trials to develop more advanced therapies, increasing awareness about the condition and available therapeutics and advancements in the development of novel therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with the various therapeutics, the high cost of the treatment, limited efficacy of the current treatments, unmet needs and uncertainties regarding treatment are the factors expected to hamper the market.

Segment Analysis

The global Parkinson’s disease therapeutics market is segmented based on disease type, treatment, route of administration, sales channel and region.

The medications segment accounted for approximately 47.4% of the Parkinson’s disease therapeutics market share

The medications segment is expected to hold the largest market share over the forecast period. Developed more than 30 years ago, levodopa is often regarded as the gold standard of Parkinson's therapy. Levodopa works by crossing the blood-brain barrier, the elaborate meshwork of fine blood vessels and cells that filter blood reaching the brain, where it is converted into dopamine. The addition of carbidopa prevents levodopa from being metabolized in the gastrointestinal tract, liver and other tissues, allowing more of it to reach the brain.

For instance, on January 10, 2023, Mitsubishi Tanabe Pharma Corporation released that its wholly-owned subsidiary, NeuroDerm Ltd. released the positive top-line results that meet its key endpoints from the phase 3 clinical trials of ND0612 (BouNDless Trial), a Parkinson's disease drug candidate. ND0612 is the first liquid formulations of levodopa and carbidopa to be administered subcutaneously to conveniently achieve steady-state levodopa plasma levels. There is an ongoing unmet need for treatment innovation for people with Parkinson's disease, as oral levodopa/carbidopa treatments yield a variable and unfavorable pharmacokinetic profile to maintain a stable clinical response.

Additionally, on September 14, 2020, Neurocrine Biosciences, Inc. launched 50 mg capsules of ONGENTYS (opicapone), the first and only FDA-approved once-daily catechol-O-methyltransferase (COMT) inhibitor, are available by prescription in the United States. ONGENTYS was approved by the U.S. Food and Drug Administration (FDA), as an add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing ""off"" episodes.

Bromocriptine, pergolide, pramipexole and ropinirole are medications that mimic the role of chemical messengers in the brain, causing the neurons to react as they would to dopamine. They can be prescribed alone or with levodopa and may be used in the early stages of the disease or administered to lengthen the duration of the effectiveness of levodopa.

Selegiline medication slows down the activity of the enzyme monoamine oxidase B (MAO-B), the enzyme that metabolizes dopamine in the brain, delaying the breakdown of naturally occurring dopamine and dopamine formed from levodopa. When taken in conjunction with levodopa, selegiline may enhance and prolong the effectiveness of levodopa.

Geographical Analysis

North America accounted for approximately 43.3% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing demand for Parkinson’s disease therapeutics. North America especially the United States is very well-known for its strong presence of major players such as pharmaceutical companies. This presence of major players in the region developing more advanced therapeutics for the treatment of Parkinson’s disease.

For instance, on May 21, 2020, Sunovion Pharmaceuticals Inc. cleared the U.S. Food and Drug Administration (FDA) approved KYNMOBI (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). OFF episodes are the re-emergence or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. They may be characterized, in part, by tremors, stiffness, slowed movement or other symptoms. These disruptive episodes can occur in the morning upon waking and throughout the day. KYNMOBI dissolves under the tongue to help people with PD improve their OFF symptoms as needed.

In addition, there is an increasing demand for Parkinson’s disease therapeutics due to the increasing prevalence of Parkinson’s disease especially in the United States. For instance, according to the Parkinson's Foundation, nearly one million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. Parkinson's is the second-most common neurodegenerative disease after Alzheimer's disease. Nearly 90,000 people in the U.S. are diagnosed with PD each year.

Competitive Landscape

The major global players in the Parkinson’s disease therapeutics market include UCB S.A., AbbVie Inc., Acadia Pharmaceuticals Inc., Abbott Laboratories, Kyowa Kirin Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eisai Co., Ltd., Supernus Pharmaceuticals, Inc. and Acorda Therapeutics, Inc. among others.

Key Developments
• On February 1, 2021, Eisai Co., Ltd. released that Eisai Korea Inc., Eisai’s subsidiary in South Korea, launched the Parkinson’s disease treatment Equfina (safinamide mesilate, “safinamide”). Safinamide is a selective monoamine oxidase B (MAO-B) inhibitor, which reduces the degradation of excreted dopamine, helping to maintain the density of dopamine in the brain. Additionally, safinamide blocks sodium ion channels and inhibits glutamate release, and as such has potential as a new Parkinson’s disease treatment that possesses both dopaminergic and non-dopaminergic mechanisms.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global Parkinson’s disease therapeutics market. The coronavirus disease 2019 (COVID-19) pandemic led to disruptions in ongoing clinical trials for Parkinson's disease therapeutics. Many trials were temporarily suspended or delayed due to restrictions on in-person visits, patient enrollment challenges and prioritization of resources towards COVID-19 research and response efforts. These disruptions slowed down the development and regulatory approval of novel therapies.

Market Segmentation

By Disease Type
• Familial Parkinson’s Disease
• Idiopathic Parkinson’s Disease
• Induced Parkinsonism

By Treatment
• Medications
Dopamine Agonists
Levodopa
Adenosine Blockers
Others
• Deep Brain Stimulation Systems
• Others

By Route of Administration
• Oral
• Transdermal
• Intravenous
• Others

By Sales Channel
• Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
• End-User
Hospitals
Specialty Clinics
Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report?
• To visualize the global parkinson’s disease therapeutics market segmentation based on disease type, treatment, route of administration, sales channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of Parkinson’s disease therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global parkinson’s disease therapeutics market report would provide approximately 61 tables, 56 figures and 189 Pages.

Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies